Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2019-08-12 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Indoco Remedies Limited's Clinical Research Organisation (CRO) cleared a USFDA inspection with zero Form 483 observations. It is addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is a corporate announcement about regulatory inspection results, not a financial report, earnings release, or management discussion. The document length is 4201 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no detailed financial data, no meeting materials, no voting results, no executive changes, no legal proceedings, no capital changes, and no merger activity. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-08-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a notice about a scheduled conference call to discuss the 1QFY20 results of Indoco Remedies Limited. It includes details about the date, time, dial-in numbers, and the management participants. There are no actual financial statements or detailed financial analysis included in the text. The document is essentially an announcement of a conference call, not the transcript or the financial report itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, but since this is a schedule/announcement of the call, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. However, given the options and the nature of the document, the closest specific category is Call Transcript (CT) if it were the transcript, but since it is only the schedule, it is not a transcript. Hence, the best fit is Regulatory Filings (RNS).
2019-08-09 English
Updates
AGM Information Classification · 95% confidence The document is a notice regarding the Seventy Second Annual General Meeting (AGM) of Indoco Remedies Limited, including details about the date, venue, remote e-voting procedures, and proxy information. It references the Annual Report for the financial year 2018-19 but does not contain the report itself. The document is primarily an announcement of the AGM and voting process, not the full Annual Report or financial statements. The length is about 5795 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2019-08-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated July 26, 2019, announcing that Indoco Remedies Limited has received the Establishment Inspection Report (EIR) from the USFDA for their Goa plants. It is addressed to stock exchanges and references a regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The content is a company announcement about regulatory approval and inspection results, not a financial report, earnings release, or detailed management discussion. The document length is 3581 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, or transcript. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2019-07-26 English
Updates
Regulatory Filings
2019-07-16 English
Press Release
Regulatory Filings
2019-07-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.